Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triphosphate SCHEMBL454437 | 0.98 | FDPS (0.41) | FDPSBLMTDP1BTN3A1 | |
| Pyrophosphoric Acid SCHEMBL3175309 | 0.88 | FDPS (0.53) | FDPSBLMTDP1 | |
| Triphosphate SCHEMBL153616 | 0.86 | FDPS (0.32) | FDPSBLMTDP1BTN3A1 | |
| Pyrimidine SCHEMBL27738489 | 0.84 | FDPS (0.38) | FDPSBLMTDP1 | |
| Triphosphate SCHEMBL27789890 | 0.84 | TDP1 (0.43) | FDPSBLMTDP1BTN3A1 | |
| Triphosphate SCHEMBL12541906 | 0.83 | FDPS (0.30) | FDPSBLMTDP1 | |
| Pyrimidine SCHEMBL29228083 | 0.82 | BTN3A1 (0.39) | FDPSBLMTDP1BTN3A1 | |
| Triphosphate SCHEMBL28958469 | 0.82 | TDP1 (0.41) | FDPSBLMTDP1BTN3A1 | |
| Pyrimidine SCHEMBL988740 | 0.77 | FDPS (0.34) | FDPSTDP1BTN3A1 | |
| Pyrimidine SCHEMBL454436 | 0.77 | FDPS (0.34) | FDPSTDP1BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612047-B2 | Degradation-resistant mononucleoside phosphate compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | claimed |
| US-20090076256-A1 | DEGRADATION-RESISTANT MONONUCLEOSIDE PHOSPHATE COMPOUNDS | DOUGLASS III JAMES G | 2009-03-19 | — | — | US | claimed |
| CN-109232693-A | A kind of synthetic method of nucleosides tetraphosphate | 上海交通大学 | 2019-01-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076256-A1 | DEGRADATION-RESISTANT MONONUCLEOSIDE PHOSPHATE COMPOUNDS | PNKP, ENTPD5, ENPP1 | FDPS 184/4885BLM 454/4885TDP1 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.